Should you buy Aclaris Therapeutics (ACRS)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Heavy Cash Burn→Stable
- Declining Revenue→Stable
- Losses Contained Beats Estimates→Stable
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Cash Burn
Trip ifFCF burn narrows to less than 200% of revenue from the current 511%.
- P2Declining Revenue
Trip ifQuarterly revenue exceeds $3M from $1.63M in the June 2026 quarter.
- P3Losses Contained Beats Estimates
Trip ifEPS loss exceeds $0.25 per share in any quarter.
- P4Large Analyst Target Upside
Trip ifAnalyst target falls below $5 from the current $8.86.
- P5Pullback In Rising Trend
Trip ifPrice falls below the $3.49 stop level, more than 7% under the current $3.75.
How the engine reached this verdict
TrendMatrix's engine output for Aclaris Therapeutics, Inc. (ACRS) is SELL_IF_HOLDING with medium conviction, score 5.0/10 at $3.96. The earnings proximity gate failed, producing a SELL engine output.
The dominant failed gate is earnings proximity (6d<=7d). SELL flips back toward HOLD if earnings proximity recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.1>=5.5.
On the bull side: Recent Analyst detected in news. On the bear side: Concentration risk — Counterparty: Biosion; Quality below floor (2.1 < 4.0). Active engine warnings: Quality below floor (2.1 < 4.0), V9 Gate Failed: EARNINGS_PROXIMITY:6d<=7d.
The engine's exit framework anchors to a tactical sell band near $3.96, with structural invalidation at $3.68. The asymmetric R:R against a reversal hypothesis is 8.11 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: AVOID at this asymmetry level (no fresh-capital deployment).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ACRS — 10-dimension breakdown →
Bull case
- ▸Recent Analyst detected in news
Bear case
- ▸Concentration risk — Counterparty: Biosion
- ▸Quality below floor (2.1 < 4.0)